These in vivo tumor-promoting effects of PAQR8 were attributable to its ability to promote tumor cell survival in response to Her2 downregulation or pharmacologic inhibition, estrogen deprivation or anti-estrogen therapy, or treatment with the chemotherapeutic agents doxorubicin or docetaxel. Here, ERBB2 is linked to neoplasm.